People with a history of cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia after age 70.
Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A new study shows how cellular “housekeeping” protects some neurons against the toxic proteins of Alzheimer’s disease and suggests new treatment possibilities.
Increasingly, transformative therapies are being launched via startups emerging from university research labs, including those at Columbia’s Vagelos College of Physicians and Surgeons.
Scientists initially believed Alzheimer's would be a simple, straightforward problem to solve, but now Columbia researchers are looking for unusual and untried solutions.
Columbia neurologists found that a test used to measure Alzheimer's disease proteins in spinal fluid can be used to determine whether patients have the disease or other forms of dementia.
A newly discovered function for the ApoE4 gene, the strongest genetic risk factor for Alzheimer’s disease, may help explain how the gene causes cognitive decline.
A new anti-inflammatory drug may offer hope for people with a progressive form of MS. In a phase 2 trial, the drug slowed brain atrophy in people with the disease.